NR AOXQ
AU Osterloh,P.; Bischoff,F.; Rammensee,H.G.; Schild,H.; Stoltze,L.
TI Characterization of prion protein specific T cells
QU International Conference - Prion diseases: from basic research to intervention concepts - TSE-Forum, 08.10.-10.10.2003, Gasteig, München - Poster session - BR-44
PT Konferenz-Poster
AB
One of the most promising approaches for treatment of prion diseases currently available is an immune therapy. This may include the possibility of immunization with recombinant prion protein (PrP) or parts thereof for the induction of PrP specific antibodies, since treatment with PrP specific antibodies results in prevention and reversion of disease progress (White et al., 2003). The induction of an efficient immune response by foreign PrP molecules is possible because of the presentation of species specific peptides from PrP by major histocompatibility complex (MHC) molecules which are recognized by T cells of the host organism. This was demonstrated by our recent observation that mouse CD4+ T cells differentiate between sheep and mouse PrP (Stoltze et al., 2003). To understand the induction of the immune response against PrP in more details we are currently further characterising these T cells. Additionally, preliminary results indicate that also in humans T cells specific for foreign PrP molecules exist.
Reference List
Stoltze,L., Rezaei H, Jung G, Grosclaude,J., Debey,P., Schild,H., and Rammensee,H.G. (2003). CD4+-T cell mediated immunity against prion proteins. Cell Mol Life Sci. 60, 629-638.
White,A.R., Enever,P., Tayebi,M., Mushens,R., Linehan,J., Brandner,S., Anstee,D., Collinge,J., and Hawke,S. (2003). Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 422, 80-83.
AD P. Osterloh, H.-G. Rammensee, H. Schild, L. Stoltze, Institute for Cell Biology, Department of Immunology, University of Tübingen, Germany; F. Bischoff, Department of Neurology, University of Tübingen, Germany.; L. Stoltze, Current address: MRC Prion Unit, Department of Neurodegenerative Diseases, Institute of Neurology, University of London, Queen Square, London WC1N 3BG, United Kingdom
SP englisch
PO Deutschland